Korea Investment Partners participated in BreezeBio's $60M Series B round (led by DSC Investment) on Feb 25, 2026.
Breeze Bio is focused on the development of genetic medicine, specifically targeting the delivery of genetic payloads to treat autoimmune diseases
Breeze Bio is focused on the development of genetic medicine, specifically targeting the delivery of genetic payloads to treat autoimmune diseases. Utilizing their NanoGalaxy platform, they aim to restore immune balance and provide targeted cures.